Northwest Wealth Management LLC Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

view original post

Northwest Wealth Management LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 37.4% in the first quarter, HoldingsChannel reports. The institutional investor owned 2,039 shares of the company’s stock after purchasing an additional 555 shares during the period. Northwest Wealth Management LLC’s holdings in Johnson & Johnson were worth $361,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Family CFO Inc purchased a new stake in Johnson & Johnson during the fourth quarter worth approximately $26,000. Steward Financial Group LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth $34,000. Joseph P. Lucia & Associates LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at $38,000. Advocacy Wealth Management Services LLC raised its position in Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $49,000. 68.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent research reports. Daiwa Capital Markets began coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating for the company. UBS Group dropped their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. SVB Leerink lowered their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Up 0.7 %

NYSE:JNJ opened at $173.68 on Wednesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The company has a market capitalization of $457.02 billion, a price-to-earnings ratio of 25.28, a price-to-earnings-growth ratio of 3.27 and a beta of 0.63. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The stock has a 50-day simple moving average of $176.04 and a 200 day simple moving average of $174.37.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.48 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.60%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.